

After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
You can purchase shares of Heron Therapeutics (NASDAQ:HRTX) through any online brokerage.
Other companies in Heron Therapeutics’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Heron Therapeutics has a consensus price target of $6.50.
The stock price for Heron Therapeutics (NASDAQ: HRTX) is $0.304 last updated October 27, 2026 at 7:44 AM EDT.
There are no upcoming dividends for Heron Therapeutics.
Heron Therapeutics does not have any upcoming earnings scheduled.
There is no upcoming split for Heron Therapeutics.
Heron Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's...